{
  "trial_id": "NCT03936270",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study;",
      "label": "met"
    },
    {
      "criterion": "Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;",
      "label": "met"
    },
    {
      "criterion": "18 years of age or older;",
      "label": "met"
    },
    {
      "criterion": "Patient agrees not to participate in another interventional study while on treatment;",
      "label": "met"
    },
    {
      "criterion": "Histologically diagnosed endometrioid or high-grade serous ovarian cancer, estrogen (ER) and/or progesterone (PR) receptor positive (defined as > 10% by immunohistochemistry);",
      "label": "met"
    },
    {
      "criterion": "Patients must have completed 2 previous courses of chemotherapy: The penultimate regimen must be a platinum-based chemotherapy course prior to enrolment on the study;",
      "label": "met"
    },
    {
      "criterion": "Formalin fixed, paraffin embedded tumor sample from the primary tumor must be available for central testing;",
      "label": "met"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2;",
      "label": "met"
    },
    {
      "criterion": "Adequate bone marrow function at screening: Absolute Neutrophil Count (ANC) \u2265 1,500/mm\u00b3 (\u2265 1.5x10^9/L);",
      "label": "met"
    },
    {
      "criterion": "Adequate liver function at screening: Total serum bilirubin \u2264 1.5 x upper limit of normal (ULN) (\u2264 3.0 x ULN if Gilbert Syndrome);",
      "label": "met"
    },
    {
      "criterion": "Adequate renal function at screening: Serum creatinine \u2264 1.5 x ULN or estimated creatinine clearance \u2265 50mL/min;",
      "label": "met"
    },
    {
      "criterion": "Evidence of non-childbearing potential: Postmenopausal (defined as at least 1 year without any menses) prior to screening,",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with a known hypersensitivity to Palbociclib or Letrozole or any of the excipients of the product;",
      "label": "triggers"
    },
    {
      "criterion": "Previous treatment with CDK inhibitors or endocrine therapy;",
      "label": "triggers"
    },
    {
      "criterion": "Persistent toxicities (grade 2 or greater) caused by previous cancer therapy (excluding alopecia);",
      "label": "triggers"
    },
    {
      "criterion": "Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma curatively treated with no evidence of disease for 3 years;",
      "label": "unknown"
    },
    {
      "criterion": "Patients receiving any chemotherapy, radiotherapy, within 3 weeks from the last dose prior to study entry;",
      "label": "triggers"
    },
    {
      "criterion": "Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required;",
      "label": "triggers"
    }
  ],
  "notes": "The patient has a history of breast cancer and is currently undergoing treatment. She has completed two previous courses of chemotherapy and has demonstrated disease progression by RECIST v1.1. The patient's tumor sample from the primary tumor is available for central testing.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT03936270",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}